The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis
Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk cytogenetic MM patients, identified by specific genetic abnormalities, face poor outcomes despite recent advancements. Traditional treatments o...
Gespeichert in:
| Veröffentlicht in: | Frontiers in medicine Jg. 12; S. 1575914 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
Frontiers Media S.A
13.05.2025
|
| Schlagworte: | |
| ISSN: | 2296-858X, 2296-858X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk cytogenetic MM patients, identified by specific genetic abnormalities, face poor outcomes despite recent advancements. Traditional treatments often prove inadequate, necessitating novel regimens. This review assesses the efficacy of emerging therapies-next-generation proteasome inhibitors, immunomodulatory drugs, and CD38-targeting agents-aimed at improving outcomes for this patient subset.
A systematic review and meta-analysis were performed, analyzing data from 18 randomized controlled trials (RCTs) involving high-risk MM patients treated with new drug combinations. Data extraction, quality assessment, and meta-analysis were conducted using a Bayesian fixed-effects model.
For transplant-eligible patients, CD38-based therapies reduced progression or death risk by 33% during induction and 48% during maintenance. They improved progression-free survival (PFS) by 38% in induction and 57% in maintenance and increased minimal residual disease (MRD) negativity by 38%. Dual novel drug regimens also enhanced MRD negativity, but Elotuzumab and Ixazomib regimens showed limited impact. Carfilzomib-based therapies showed varying PFS and survival benefits.
CD38-targeted regimens notably improve outcomes in high-risk cytogenetic MM, especially for transplant-eligible patients, by reducing disease progression, enhancing PFS, and increasing MRD negativity. Dual novel regimens show promise in MRD improvements. These findings support the potential of tailored therapeutic strategies to optimize patient care. |
|---|---|
| AbstractList | Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk cytogenetic MM patients, identified by specific genetic abnormalities, face poor outcomes despite recent advancements. Traditional treatments often prove inadequate, necessitating novel regimens. This review assesses the efficacy of emerging therapies-next-generation proteasome inhibitors, immunomodulatory drugs, and CD38-targeting agents-aimed at improving outcomes for this patient subset.
A systematic review and meta-analysis were performed, analyzing data from 18 randomized controlled trials (RCTs) involving high-risk MM patients treated with new drug combinations. Data extraction, quality assessment, and meta-analysis were conducted using a Bayesian fixed-effects model.
For transplant-eligible patients, CD38-based therapies reduced progression or death risk by 33% during induction and 48% during maintenance. They improved progression-free survival (PFS) by 38% in induction and 57% in maintenance and increased minimal residual disease (MRD) negativity by 38%. Dual novel drug regimens also enhanced MRD negativity, but Elotuzumab and Ixazomib regimens showed limited impact. Carfilzomib-based therapies showed varying PFS and survival benefits.
CD38-targeted regimens notably improve outcomes in high-risk cytogenetic MM, especially for transplant-eligible patients, by reducing disease progression, enhancing PFS, and increasing MRD negativity. Dual novel regimens show promise in MRD improvements. These findings support the potential of tailored therapeutic strategies to optimize patient care. IntroductionMultiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk cytogenetic MM patients, identified by specific genetic abnormalities, face poor outcomes despite recent advancements. Traditional treatments often prove inadequate, necessitating novel regimens. This review assesses the efficacy of emerging therapies—next-generation proteasome inhibitors, immunomodulatory drugs, and CD38-targeting agents—aimed at improving outcomes for this patient subset.MethodsA systematic review and meta-analysis were performed, analyzing data from 18 randomized controlled trials (RCTs) involving high-risk MM patients treated with new drug combinations. Data extraction, quality assessment, and meta-analysis were conducted using a Bayesian fixed-effects model.ResultsFor transplant-eligible patients, CD38-based therapies reduced progression or death risk by 33% during induction and 48% during maintenance. They improved progression-free survival (PFS) by 38% in induction and 57% in maintenance and increased minimal residual disease (MRD) negativity by 38%. Dual novel drug regimens also enhanced MRD negativity, but Elotuzumab and Ixazomib regimens showed limited impact. Carfilzomib-based therapies showed varying PFS and survival benefits.ConclusionCD38-targeted regimens notably improve outcomes in high-risk cytogenetic MM, especially for transplant-eligible patients, by reducing disease progression, enhancing PFS, and increasing MRD negativity. Dual novel regimens show promise in MRD improvements. These findings support the potential of tailored therapeutic strategies to optimize patient care. Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk cytogenetic MM patients, identified by specific genetic abnormalities, face poor outcomes despite recent advancements. Traditional treatments often prove inadequate, necessitating novel regimens. This review assesses the efficacy of emerging therapies-next-generation proteasome inhibitors, immunomodulatory drugs, and CD38-targeting agents-aimed at improving outcomes for this patient subset.IntroductionMultiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk cytogenetic MM patients, identified by specific genetic abnormalities, face poor outcomes despite recent advancements. Traditional treatments often prove inadequate, necessitating novel regimens. This review assesses the efficacy of emerging therapies-next-generation proteasome inhibitors, immunomodulatory drugs, and CD38-targeting agents-aimed at improving outcomes for this patient subset.A systematic review and meta-analysis were performed, analyzing data from 18 randomized controlled trials (RCTs) involving high-risk MM patients treated with new drug combinations. Data extraction, quality assessment, and meta-analysis were conducted using a Bayesian fixed-effects model.MethodsA systematic review and meta-analysis were performed, analyzing data from 18 randomized controlled trials (RCTs) involving high-risk MM patients treated with new drug combinations. Data extraction, quality assessment, and meta-analysis were conducted using a Bayesian fixed-effects model.For transplant-eligible patients, CD38-based therapies reduced progression or death risk by 33% during induction and 48% during maintenance. They improved progression-free survival (PFS) by 38% in induction and 57% in maintenance and increased minimal residual disease (MRD) negativity by 38%. Dual novel drug regimens also enhanced MRD negativity, but Elotuzumab and Ixazomib regimens showed limited impact. Carfilzomib-based therapies showed varying PFS and survival benefits.ResultsFor transplant-eligible patients, CD38-based therapies reduced progression or death risk by 33% during induction and 48% during maintenance. They improved progression-free survival (PFS) by 38% in induction and 57% in maintenance and increased minimal residual disease (MRD) negativity by 38%. Dual novel drug regimens also enhanced MRD negativity, but Elotuzumab and Ixazomib regimens showed limited impact. Carfilzomib-based therapies showed varying PFS and survival benefits.CD38-targeted regimens notably improve outcomes in high-risk cytogenetic MM, especially for transplant-eligible patients, by reducing disease progression, enhancing PFS, and increasing MRD negativity. Dual novel regimens show promise in MRD improvements. These findings support the potential of tailored therapeutic strategies to optimize patient care.ConclusionCD38-targeted regimens notably improve outcomes in high-risk cytogenetic MM, especially for transplant-eligible patients, by reducing disease progression, enhancing PFS, and increasing MRD negativity. Dual novel regimens show promise in MRD improvements. These findings support the potential of tailored therapeutic strategies to optimize patient care. |
| Author | Chen, Wenming Zhou, Huixing |
| AuthorAffiliation | Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Multiple Myeloma Research Center of Beijing , Beijing , China |
| AuthorAffiliation_xml | – name: Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Multiple Myeloma Research Center of Beijing , Beijing , China |
| Author_xml | – sequence: 1 givenname: Huixing surname: Zhou fullname: Zhou, Huixing – sequence: 2 givenname: Wenming surname: Chen fullname: Chen, Wenming |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40432724$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVks1u1TAQhSNUREvpA7BBXrLJxX_xTdggVPFTqRKbIrGzJvY41yWxL7ZTlKfhVcmll6pd2Zo5_s5Yc15WJyEGrKrXjG6EaLt3bkK74ZQ3G9Zsm47JZ9UZ552q26b9cfLoflpd5HxLKWWCN5KJF9WppFLwLZdn1Z-bHRJ0zhswC4mOBPxNbJoHknDwE4ZMfCAlIRQfhkN3XIj1MISY0ZKdH3Z18vknMUuJAwYs3pBpHovfj0imBcc4AdmvrzGU_J4AyUsuOMFBN_qCCcqccHW786szBEsmLFBDgHHJPr-qnjsYM14cz_Pq--dPN5df6-tvX64uP17XRnJaamx6YZjiQknY9s4wZxvLqWO96Ju276jpQbUgpQJojARj6HYtUWc71SvlxHl1dc-1EW71PvkJ0qIjeP2vENOgIa0zj6h5q1BZ1VvRgWyU7VtmacccV8gEglpZH-5Z-7lfl2TWnycYn0CfdoLf6SHeacYZVZKxlfD2SEjx14y56Mlng-MIAeOcteCMb1vRSLpK3zw2e3D5v-JVwO4FJsWcE7oHCaP6kCR9SJI-JEkfkyT-Al5Twck |
| Cites_doi | 10.1182/blood-2023-177546 10.1111/cyt.13280 10.1182/blood-2012-05-432203 10.1136/bmj.d5928 10.3390/cancers15143687 10.3390/curroncol30110705 10.1182/blood-2016-01-631200 10.1056/NEJMoa1714678 10.1136/bmj.n71 10.1002/ajh.25791 10.1016/j.ctrv.2015.07.005 10.1056/NEJMoa1817249 10.3324/haematol.2023.284662 10.1016/s1470-2045(22)00738-0 10.1182/blood.2020008787 10.1016/s0140-6736(19)31240-1 10.1016/s2352-3026(20)30354-9 10.1016/s2352-3026(22)00263-0 10.1016/s1470-2045(22)00693-3 10.3390/cancers13071668 10.1016/s2352-3026(22)00103-x 10.1038/s41598-025-85398-0 10.1002/ajh.25117 10.1056/NEJMoa2312054 10.1016/S2352-3026(22)00350-7 10.1016/s1470-2045(20)30452-6 10.1038/s41375-021-01431-x 10.1002/ajh.26590 10.1016/s0140-6736(18)33003-4 10.1200/jco.20.02060 10.1182/hematology.2021000230 10.1016/j.ccell.2019.09.006 10.1007/s12185-022-03353-5 10.1182/blood.2020005288 10.1080/14737140.2018.1490181 10.1038/s41408-020-00359-2 10.1182/blood-2018-09-874396 10.1056/NEJMoa2400712 |
| ContentType | Journal Article |
| Copyright | Copyright © 2025 Zhou and Chen. Copyright © 2025 Zhou and Chen. 2025 Zhou and Chen |
| Copyright_xml | – notice: Copyright © 2025 Zhou and Chen. – notice: Copyright © 2025 Zhou and Chen. 2025 Zhou and Chen |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fmed.2025.1575914 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2296-858X |
| ExternalDocumentID | oai_doaj_org_article_286e6d6bd39a456db81d091f26e13ea6 PMC12106411 40432724 10_3389_fmed_2025_1575914 |
| Genre | Systematic Review Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK GROUPED_DOAJ HYE KQ8 M~E OK1 PGMZT RPM ACXDI IPNFZ M48 NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c420t-e5b3c162364a7bfc1fd5d20f1b3b58b90cba68a446aa5c4acc07cba0fd96b66f3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001495342600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2296-858X |
| IngestDate | Fri Oct 03 12:44:36 EDT 2025 Thu Aug 21 18:37:44 EDT 2025 Fri Sep 05 15:59:45 EDT 2025 Sat May 31 02:13:05 EDT 2025 Sat Nov 29 07:57:49 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | multiple myeloma novel drug regimens progression-free survival CD38 antibodies meta-analysis minimal residual disease systematic review high-risk cytogenetics |
| Language | English |
| License | Copyright © 2025 Zhou and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c420t-e5b3c162364a7bfc1fd5d20f1b3b58b90cba68a446aa5c4acc07cba0fd96b66f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Edited by: Nicola Sgherza, AOU Policlinico Consorziale di Bari, Italy Deevyashali Parekh, Upstate Medical University, United States Reviewed by: Xu Hannah Zhang, City of Hope National Medical Center, United States |
| OpenAccessLink | https://doaj.org/article/286e6d6bd39a456db81d091f26e13ea6 |
| PMID | 40432724 |
| PQID | 3212783540 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_286e6d6bd39a456db81d091f26e13ea6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12106411 proquest_miscellaneous_3212783540 pubmed_primary_40432724 crossref_primary_10_3389_fmed_2025_1575914 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-05-13 |
| PublicationDateYYYYMMDD | 2025-05-13 |
| PublicationDate_xml | – month: 05 year: 2025 text: 2025-05-13 day: 13 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in medicine |
| PublicationTitleAlternate | Front Med (Lausanne) |
| PublicationYear | 2025 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Kumar (ref27) 2020; 21 Deeks (ref10) 2023 Facon (ref25) 2021; 137 Rajkumar (ref1) 2020; 95 Goldschmidt (ref13) 2022; 9 Dimopoulos (ref17) 2019; 393 Facon (ref22) 2019; 380 John (ref37) 2021; 13 Grosser (ref39) 2019; 36 Page (ref8) 2021; 372 Facon (ref28) 2019; 133 Mina (ref18) 2023; 24 Bergsagel (ref7) 2013; 121 Dimopoulos (ref6) 2015; 41 Yong (ref20) 2023; 10 Fazio (ref2) 2023; 30 Usmani (ref16) 2021; 8 Yee (ref34) 2021; 2021 Dytfeld (ref19) 2023; 24 Rajkumar (ref5) 2018; 93 Leypoldt (ref33) 2022; 36 Voorhees (ref14) 2020; 136 Rajkumar (ref4) 2020; 10 Higgins (ref9) 2011; 343 Li (ref29) 2025; 15 Rajkumar (ref36) 2022; 97 Sonneveld (ref3) 2016; 127 Hanamura (ref32) 2022; 115 Dimopoulos (ref24) 2022; 9 (ref40) 2025 Szalat (ref31) 2024; 109 Dimopoulos (ref26) 2020; 38 Moreau (ref11) 2019; 394 Mateos (ref21) 2018; 378 Medina-Herrera (ref30) 2023; 15 Richardson (ref38) 2018; 18 Sonneveld (ref12) 2024; 390 Facon (ref23) 2024; 391 Francesca Gay (ref15) 2023; 142 Stone (ref35) 2023; 34 |
| References_xml | – start-page: 241 volume-title: Cochrane handbook for systematic reviews of interventions year: 2023 ident: ref10 article-title: Chapter 10: Analysing data and undertaking meta-analyses – volume: 142 start-page: 4 year: 2023 ident: ref15 article-title: Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-Lenalidomide-dexamethasone vs carfilzomib-Lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients publication-title: Blood doi: 10.1182/blood-2023-177546 – volume: 34 start-page: 530 year: 2023 ident: ref35 article-title: Phenotypic clues that predict underlying cytogenetic/genetic abnormalities in myeloid malignancies: a contemporary review publication-title: Cytopathology doi: 10.1111/cyt.13280 – volume: 121 start-page: 884 year: 2013 ident: ref7 article-title: Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma publication-title: Blood doi: 10.1182/blood-2012-05-432203 – volume: 343 start-page: 5928 year: 2011 ident: ref9 article-title: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials publication-title: BMJ doi: 10.1136/bmj.d5928 – volume: 15 start-page: 3687 year: 2023 ident: ref30 article-title: Minimal residual disease in multiple myeloma: past, present, and future publication-title: Cancers doi: 10.3390/cancers15143687 – volume: 30 start-page: 9710 year: 2023 ident: ref2 article-title: Multiple myeloma in 2023 ways: from trials to real life publication-title: Curr Oncol doi: 10.3390/curroncol30110705 – volume: 127 start-page: 2955 year: 2016 ident: ref3 article-title: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group publication-title: Blood doi: 10.1182/blood-2016-01-631200 – volume: 378 start-page: 518 year: 2018 ident: ref21 article-title: Daratumumab plus Bortezomib, Melphalan, and prednisone for untreated myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1714678 – year: 2025 ident: ref40 – volume: 372 start-page: n71 year: 2021 ident: ref8 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ doi: 10.1136/bmj.n71 – volume: 95 start-page: 548 year: 2020 ident: ref1 article-title: Multiple myeloma: 2020 update on diagnosis, risk-stratification and management publication-title: Am J Hematol doi: 10.1002/ajh.25791 – volume: 41 start-page: 827 year: 2015 ident: ref6 article-title: Clinical characteristics of patients with relapsed multiple myeloma publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2015.07.005 – volume: 380 start-page: 2104 year: 2019 ident: ref22 article-title: Daratumumab plus Lenalidomide and dexamethasone for untreated myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa1817249 – volume: 109 start-page: 2049 year: 2024 ident: ref31 article-title: Role of minimal residual disease assessment in multiple myeloma publication-title: Haematology doi: 10.3324/haematol.2023.284662 – volume: 24 start-page: 139 year: 2023 ident: ref19 article-title: Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/s1470-2045(22)00738-0 – volume: 137 start-page: 3616 year: 2021 ident: ref25 article-title: Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma publication-title: Blood doi: 10.1182/blood.2020008787 – volume: 394 start-page: 29 year: 2019 ident: ref11 article-title: Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study publication-title: Lancet doi: 10.1016/s0140-6736(19)31240-1 – volume: 8 start-page: e45 year: 2021 ident: ref16 article-title: Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial publication-title: Lancet Haematol. doi: 10.1016/s2352-3026(20)30354-9 – volume: 9 start-page: e810 year: 2022 ident: ref13 article-title: Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial publication-title: Lancet Haematol. doi: 10.1016/s2352-3026(22)00263-0 – volume: 24 start-page: 64 year: 2023 ident: ref18 article-title: Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial publication-title: Lancet Oncol doi: 10.1016/s1470-2045(22)00693-3 – volume: 13 start-page: 1668 year: 2021 ident: ref37 article-title: Pathway-directed therapy in multiple myeloma publication-title: Cancers doi: 10.3390/cancers13071668 – volume: 9 start-page: e403 year: 2022 ident: ref24 article-title: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial publication-title: Lancet Haematol. doi: 10.1016/s2352-3026(22)00103-x – volume: 15 start-page: 9946 year: 2025 ident: ref29 article-title: VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma publication-title: Sci Rep doi: 10.1038/s41598-025-85398-0 – volume: 93 start-page: 1091 year: 2018 ident: ref5 article-title: Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management publication-title: Am J Hematol doi: 10.1002/ajh.25117 – volume: 390 start-page: 301 year: 2024 ident: ref12 article-title: Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa2312054 – volume: 10 start-page: e93 year: 2023 ident: ref20 article-title: Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial publication-title: Lancet Haematol doi: 10.1016/S2352-3026(22)00350-7 – volume: 21 start-page: 1317 year: 2020 ident: ref27 article-title: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial publication-title: Lancet Oncol doi: 10.1016/s1470-2045(20)30452-6 – volume: 36 start-page: 885 year: 2022 ident: ref33 article-title: Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial publication-title: Leukemia doi: 10.1038/s41375-021-01431-x – volume: 97 start-page: 1086 year: 2022 ident: ref36 article-title: Multiple myeloma: 2022 update on diagnosis, risk stratification, and management publication-title: Am J Hematol doi: 10.1002/ajh.26590 – volume: 393 start-page: 253 year: 2019 ident: ref17 article-title: Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial publication-title: Lancet doi: 10.1016/s0140-6736(18)33003-4 – volume: 38 start-page: 4030 year: 2020 ident: ref26 article-title: Ixazomib as Postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial publication-title: J Clin Oncol doi: 10.1200/jco.20.02060 – volume: 2021 start-page: 37 year: 2021 ident: ref34 article-title: Minimal residual disease in multiple myeloma: why, when, where publication-title: Hematology doi: 10.1182/hematology.2021000230 – volume: 36 start-page: 471 year: 2019 ident: ref39 article-title: Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.09.006 – volume: 115 start-page: 762 year: 2022 ident: ref32 article-title: Multiple myeloma with high-risk cytogenetics and its treatment approach publication-title: Int J Hematol doi: 10.1007/s12185-022-03353-5 – volume: 136 start-page: 936 year: 2020 ident: ref14 article-title: Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial publication-title: Blood doi: 10.1182/blood.2020005288 – volume: 18 start-page: 751 year: 2018 ident: ref38 article-title: Maintenance and continuous therapy for multiple myeloma publication-title: Expert Rev Anticancer Ther doi: 10.1080/14737140.2018.1490181 – volume: 10 start-page: 2 year: 2020 ident: ref4 article-title: Multiple myeloma current treatment algorithms. Blood publication-title: Cancer J doi: 10.1038/s41408-020-00359-2 – volume: 133 start-page: 1953 year: 2019 ident: ref28 article-title: Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma publication-title: Blood doi: 10.1182/blood-2018-09-874396 – volume: 391 start-page: 1597 year: 2024 ident: ref23 article-title: Isatuximab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med doi: 10.1056/NEJMoa2400712 |
| SSID | ssj0001325413 |
| Score | 2.2914438 |
| SecondaryResourceType | review_article |
| Snippet | Multiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage. High-risk... IntroductionMultiple myeloma (MM) is a plasma cell malignancy comprising 10% of hematologic cancers, associated with bone marrow dysfunction and organ damage.... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 1575914 |
| SubjectTerms | CD38 antibodies high-risk cytogenetics Medicine minimal residual disease multiple myeloma novel drug regimens progression-free survival |
| Title | The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40432724 https://www.proquest.com/docview/3212783540 https://pubmed.ncbi.nlm.nih.gov/PMC12106411 https://doaj.org/article/286e6d6bd39a456db81d091f26e13ea6 |
| Volume | 12 |
| WOSCitedRecordID | wos001495342600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: 8C1 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: PIMPY dateStart: 20190101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ1bq9NAEMcXPYr4It6tlzKCT0I0u5tsEt88h3PQh1OKKNSnMHvJsdAm0qZCP41f1Zkkra0IvvgSyAWy5D_JzGRnfyPEK4yxcomxUZxaSlAy9JHFUEU6Sb1MAy_WjLtmE9lkks9mxfSg1RfXhPV44P7BvVW5CcYb63WB5Oy9pQCLfFylTJA6YAfbjrPiIJnq_q5oSnyk7qcxKQsrSKbAYFCVvpHck1ImR46o4_X_Lcj8s1bywPlc3BV3hqgR3vejvSeuhfq-uHU5zIs_ED9JbQhMg0C3haYCCpbBrzZXwI0XlpSqwryGrqicXBWfXWzB91V2wQMziyMuMge3bRsyKV7ZCLtaQ1huw6JZIgwM1vU7QPhNgIbFnswM_UIYwNrDMrQY4YA8eSi-XJx_PvsQDa0XIpeouI1CarWThunymNnKycqnXsWVtNqmuS1iZ9HkSLkkYuoSdC7O6FBc-cJYYyr9SJzUTR2eCChyCmps4ZC-BElWKHaJ9JnIsUKnVeZG4vVOh_J7T9goKTNh0UoWrWTRykG0kThlpfYXMhy7O0AmUw4mU_7LZEbi5U7nkl4mniHBOjSbdamZd9_9ChuJx73u-1sxhkhlioaQH1nE0ViOz9Tzbx2wmyFtJpHy6f8Y_TNxm58IVzAo_VyctKtNeCFuuh_tfL0ai-vZLOu2OW3zMzkWN07PJ9NP4-4Fob3px8vp11_Grxhi |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+efficacy+of+new+drug+regimens+in+treating+newly+diagnosed+high-risk+cytogenetic+multiple+myeloma+patients%3A+a+systematic+literature+review+and+meta-analysis&rft.jtitle=Frontiers+in+medicine&rft.au=Zhou%2C+Huixing&rft.au=Chen%2C+Wenming&rft.date=2025-05-13&rft.issn=2296-858X&rft.eissn=2296-858X&rft.volume=12&rft.spage=1575914&rft_id=info:doi/10.3389%2Ffmed.2025.1575914&rft_id=info%3Apmid%2F40432724&rft.externalDocID=40432724 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon |